期刊文献+

^(99m)Tc标记4-甲基咪唑双膦酸配合物的动物体内分布及骨显像性能 被引量:1

Biodistribution and Bone Imaging Property of ^(99m)Tc-M_4IDP
下载PDF
导出
摘要 对唑来膦酸衍生物1-羟基-2-(4-甲基-1H-咪唑-1-基)乙烷-1,1-双膦酸(M4IDP)进行99mTc标记,得到99mTc-M4IDP,研究了其小鼠体内分布和兔骨显像性能。结果表明,在小鼠注射99mTc-M4IDP60 min后,骨(7.85±0.73)%/g和关节(14.29±0.53)%/g摄取都达到最大值,肌肉(0.45±0.03)%/g和血(1.88±0.22)%/g的摄取很低。兔经注射99mTc-M4IDP 1 h后即可获得清晰的骨显像,本底吸收很低。表明99mTc-M4IDP是一种软组织代谢速率快、骨吸收高的性能优异的新型骨显像剂。 The compound 1-Hydroxy-2-(4-methyl-lH-imidazoleyl)-ethylidene-l,l-bis- phosphonate (MflDP) was labeled by 99mTc to afford 99mTc-M41DP. The biodistribution in mice and bone image in rabbit for 99mTc-M4IDP were studied. The results showed that the uptakes of bone and jiont of 99mTc-M4IDP in mice reached the maximum of 7.85 ± O. 73 %/g and 14.29 ± 0.53 %/g respectively at 60 min post injection. It also had low uptake in muscle (0.45 ± 0.03 %/g) and blood (1.88 ± 0.22 %/g) , respectively. The clear bone image of rabbit was obtained at 1 h post injection of 99mTc-M4IDP. The perliminary investgation indicated that the 99mTc-M4IDP is an excellent bone imaging agent with rapid elimination in soft tissue and high uptake in bone.
出处 《江南大学学报(自然科学版)》 CAS 2013年第4期465-469,共5页 Joural of Jiangnan University (Natural Science Edition) 
基金 国家自然科学基金项目(20801024) 江苏省自然科学基金项目(BK2009077)
关键词 1-羟基-2-(4-甲基-1H-咪唑-1-基)乙烷-1 1-双膦酸 ^99MTC标记 动物分布 骨显像剂 M4 IDP, 99m Tc-labeled, biodistribution, bone imaging agent
  • 相关文献

参考文献14

  • 1Rogers M J, Watts D J, Russell R G G. Overview of bisphosphonates [ J ]. Caner Supplement, 1997,80 : 1652-1160.
  • 2Fleisch H. Bisphosphonates : mechanisms of action[ J]. Endocrine Reviews, 1998,19 ( 1 ) :80-100.
  • 3Russell R G G, Rogers M J. Bisphosphon ates:from the laboratory to the clinic and back again[ J ]. Bone, 1999,25 (1) :97-106.
  • 4Widler L, Jaeggi K A, Glatt M, et al. Highly potent geminal bisphosphonates, from pamidronate disodium (aredia) to zoledronic acid (zometa) [ J]. J Med Chem,2002,45:3721-3738.
  • 5Russell R G G, Watts N B, Ebetino F H, et al. Mechanisms of action of bisphosphonates : similarities and differences and their potential influence on clinical efficacy[ J]. Osteoporos Int,2008 ,19 :733 -759.
  • 6Clezardin P. Anti-tumour activity of zoledronic acid[ J]. Cancer Treatment Reviews ,2005,31 :S1-S8.
  • 7Saag K, Lindsay R, Krlegunm A. Asingle zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density [ J ]. Bone ,2007,40 (5) :1238-1243.
  • 8Rosen L S, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in :he treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma [ J]. Cancer, 2003,98 ( 8 ) : 1735-1744.
  • 9刘晓梅,李增炎.放射性核素骨显像在临床骨科的新进展[J].中国骨与关节损伤杂志,2005,20(5):356-358. 被引量:10
  • 10Vbrbeke K, Rozenski J, Cleynhens B, et al. Development of a conjugate of 99Tcm-EC with aminomethylenediphosphosphonate in the search for a bone tracer with fast clearance from soft tissue [ J ]. Bioconjugate Chem,2002,13 (1) :6-22.

二级参考文献16

共引文献11

同被引文献11

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部